2247 related articles for article (PubMed ID: 8297135)
1. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.
Kusano A; Ohta S; Shitara K; Hanai N
Anticancer Res; 1993; 13(6A):2207-12. PubMed ID: 8297135
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies.
Ohta S; Igarashi S; Honda A; Sato S; Hanai N
Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645
[TBL] [Abstract][Full Text] [Related]
3. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin G-class mouse monoclonal antibodies to major brain gangliosides.
Schnaar RL; Fromholt SE; Gong Y; Vyas AA; Laroy W; Wayman DM; Heffer-Lauc M; Ito H; Ishida H; Kiso M; Griffin JW; Shiekh KA
Anal Biochem; 2002 Mar; 302(2):276-84. PubMed ID: 11878808
[TBL] [Abstract][Full Text] [Related]
5. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.
Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ
Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480
[TBL] [Abstract][Full Text] [Related]
6. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
[TBL] [Abstract][Full Text] [Related]
7. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
Helfand SC; Hank JA; Gan J; Sondel PM
Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
[TBL] [Abstract][Full Text] [Related]
9. Binding and internalization of anti-sarcoma IgG and IgM antibodies.
Chao TC; Walter RJ; Greager JA
J Surg Res; 1997 Jun; 70(1):27-33. PubMed ID: 9228923
[TBL] [Abstract][Full Text] [Related]
10. Recombinant antibodies against ganglioside expressed on tumor cells.
Hanai N; Nakamura K; Shitara K
Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
[TBL] [Abstract][Full Text] [Related]
11. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis.
Cheresh DA; Rosenberg J; Mujoo K; Hirschowitz L; Reisfeld RA
Cancer Res; 1986 Oct; 46(10):5112-8. PubMed ID: 3019521
[TBL] [Abstract][Full Text] [Related]
12. Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside.
Chapman PB; Yuasa H; Houghton AN
J Immunol; 1990 Aug; 145(3):891-8. PubMed ID: 1695649
[TBL] [Abstract][Full Text] [Related]
13. Human monoclonal antibody to tumor-associated ganglioside GD2.
Katano M; Saxton RE; Irie RF
J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3.
Hersey P; Schibeci SD; Townsend P; Burns C; Cheresh DA
Cancer Res; 1986 Dec; 46(12 Pt 1):6083-90. PubMed ID: 3022915
[TBL] [Abstract][Full Text] [Related]
15. Generation of human IgG, IgA, and IgM anti-melanoma monoclonal antibodies utilizing lymphocytes of an actively immunized melanoma patient.
Abdel-wahab ZA; Gillanders WE; Darrow TL; Seigler HF
Hum Antibodies Hybridomas; 1992 Jan; 3(1):32-9. PubMed ID: 1576321
[TBL] [Abstract][Full Text] [Related]
16. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells.
Lloyd KO; Gordon CM; Thampoe IJ; DiBenedetto C
Cancer Res; 1992 Sep; 52(18):4948-53. PubMed ID: 1516051
[TBL] [Abstract][Full Text] [Related]
17. An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo.
Dohi T; Nores G; Hakomori S
Cancer Res; 1988 Oct; 48(20):5680-5. PubMed ID: 3167827
[TBL] [Abstract][Full Text] [Related]
18. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
19. A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels.
Shockley TR; Lin K; Sung C; Nagy JA; Tompkins RG; Dedrick RL; Dvorak HF; Yarmush ML
Cancer Res; 1992 Jan; 52(2):357-66. PubMed ID: 1728407
[TBL] [Abstract][Full Text] [Related]
20. Incorporation, remodeling and re-expression of exogenous gangliosides in human cancer cell lines in vitro and in vivo.
Nishio M; Furukawa K
Nagoya J Med Sci; 2004 May; 67(1-2):35-44. PubMed ID: 15279066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
